

---

**Revision requested for PRO\_2019\_9**

2 messages

**MICHAL SCHWARTZMAN (Prostaglandins and Other Lipid Mediators)**

&lt;EvisSupport@elsevier.com&gt;

Reply-To: polm@nymc.edu

To: yudy.tjahjono@ukwms.ac.id

Thu, May 16, 2019 at  
1:30 AM

Ref: PRO\_2019\_9

Title: Evaluation of Analgesic and Antiplatelet Activity of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid

Journal: Prostaglandins and Other Lipid Mediators

Dear Mr. tjahjono,

Thank you for submitting your manuscript to Prostaglandins and Other Lipid Mediators. I have completed the review of your manuscript and a summary is appended below. The reviewers recommend reconsideration of your paper following major revision. I invite you to resubmit your manuscript after addressing all reviewer comments.

When resubmitting your manuscript, please carefully consider all issues mentioned in the reviewers' comments, outline every change made point by point, and provide suitable rebuttals for any comments not addressed.

To submit your revised manuscript:

- Log into EVISE® at: [http://www.evise.com/evise/faces/pages/navigation/NavController.jsp?JRNL\\_ACR=PRO](http://www.evise.com/evise/faces/pages/navigation/NavController.jsp?JRNL_ACR=PRO)
- Locate your manuscript under the header 'My Submissions that need Revisions' on your 'My Author Tasks' view
- Click on 'Agree to Revise'
- Make the required edits
- Click on 'Complete Submission' to approve

**What happens next?**

After you approve your submission preview you will receive a notification that the submission is complete. To track the status of your paper throughout the editorial process, log in to Evise® at: [http://www.evise.com/evise/faces/pages/navigation/NavController.jsp?JRNL\\_ACR=PRO](http://www.evise.com/evise/faces/pages/navigation/NavController.jsp?JRNL_ACR=PRO).

**Enrich your article to present your research with maximum impact.** This journal supports the following [Content Innovations](#):

Data in Brief (optional)

We invite you to convert your supplementary data (or a part of it) into a Data in Brief article. Data in Brief articles are descriptions of the data and associated metadata which are normally buried in supplementary material. They are actively reviewed, curated, formatted, indexed, given a DOI and freely available to all upon publication. Data in Brief should be uploaded with your revised manuscript directly to Prostaglandins and Other Lipid Mediators. If your Prostaglandins and Other Lipid Mediators research article is accepted, your Data in Brief article will automatically be transferred over to our new, fully Open Access journal, Data in Brief, where it will be editorially reviewed and published as a separate data article upon acceptance. The Open Access fee for Data in Brief is \$500.

Please just fill in the template found here:

[http://www.elsevier.com/inca/publications/misc/dib\\_data%20article%20template\\_for%20other%20journals.docx](http://www.elsevier.com/inca/publications/misc/dib_data%20article%20template_for%20other%20journals.docx). Then, place all Data in Brief files (whichever supplementary files you would like to include as well as your completed Data in Brief template) into a .zip file and upload this as a Data in Brief item alongside your Prostaglandins and Other Lipid Mediators revised manuscript. Note that only this Data in Brief item will be transferred over to Data in Brief, so ensure all of your relevant Data in Brief documents are zipped into a single file. Also, make sure you change references to supplementary material in your Prostaglandins and Other Lipid Mediators manuscript to reference the Data in Brief article where appropriate.

Questions? Please send your inquiries to [dib@elsevier.com](mailto:dib@elsevier.com). Example Data in Brief can be found here: <http://www.sciencedirect.com/science/journal/23523409>

I look forward to receiving your revised manuscript as soon as possible.

Kind regards,

Dr SCHWARTZMAN  
Editor-in-Chief  
Prostaglandins and Other Lipid Mediators

**Comments from the editors and reviewers:**

**-Reviewer 1**

-

Kuncoro Foe and colleagues demonstrated that a new compound related to salicylic acid namely 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid had an excellent analgesic effect with no toxicity impact, better than acetylsalicylic acid. They synthesized this new compound which is a relatively simple and easy method. The experimental data convincing and the written results and methods are understandable. However, minor comment will be addressed before accepting the publication.

Description of the histological layers on the Fig.2 is essential to understand the orientation. The authors can keep the abbreviations on the figure and detailed microscopic layers in the figure legend. On Fig.2A, 400X can be removed and it does not say anything. Bars as mentioned in the figure legend has 200 but, on the figure, as 1 mm. Correct it. Authors are advised to keep the same magnification in all three pictures. Most importantly, the pictures are with low quality and blur. Better new pictures with focused plane improve the results.

**-Reviewer 2**

-

There significant novelty in this research paper, the authors develop new derivation drug form of aspirin for better platelet aggregation and lower oral toxicity than the conventional aspirin. The *in vivo* experiments were conducted with detail to provide concise description of synthesized drug. The paper can be accepted after following these revisions.

1. Section 2.2, 3.1, 4.1 should be changed into characterization.
2. There are two lines in Figure 3 and 4, please put legend to define each lines.
3. In section 4.1, the authors mention that they use pyridine as the catalyst. Based on scheme 1, pyridine is actually transformed into salt form. Normally, catalyst does not involve in a reaction since their purpose only lower the activation energy of the system. Please clarify the discussion in section 4.1.
4. The sentence "Pyridine could convert phenolic hydroxyl moieties into a good leaving group" is confusing. What does a good leaving group mean?
5. Please explain the reason of using acetone as the solvent. Is it possible to change it with other organic solvents to negotiate the danger of acetone toward the environment hazard?
6. In section 4.2, 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid has higher CLogP than acetylsalicylic acid, but both have same values of polarizability and CMR. Is it possible?
7. ASA has non selective inhibition toward COX-1 and COX-2, so it leads to the disruption of the integrity of healthy gastric mucosal layer. But 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid can maintain the integrity if gastric mucosal layer. Please explain it based on the concentration dependent experiment.
8. Please explain briefly the comparison of the synthesized drug and ASA for the inhibition of COX2 with regards of time dependent contact of mucosal layer.
9. There are some grammatical error in this manuscript, please check it thoroughly.

**MethodsX (optional)**

We invite you to submit a method article alongside your research article. This is an opportunity to get full credit for the time and money you have spent on developing research methods, and to increase the visibility and impact of your work.

If your research article is accepted, your method article will be automatically transferred over to the open access journal, MethodsX, where it will be editorially reviewed and published as a separate method article upon acceptance. Both articles will be linked on ScienceDirect.

Please use the MethodsX template available here when preparing your article: <https://www.elsevier.com/MethodsX-template>. Open access fees apply.

**Have questions or need assistance?**

For further assistance, please visit our [Customer Support](#) site. Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about EVISE® via interactive tutorials. You can also talk 24/5 to our customer support team by phone and 24/7 by live chat and email.

-----  
Copyright © 2018 Elsevier B.V. | [Privacy Policy](#)

Elsevier [B.V.](#), [Radarweg 29](#), [1043 NX Amsterdam](#), [The Netherlands](#), Reg. No. 33156677.

---

**Yudy Tjahjono, B.Sc., M.Sc.Biol.** <yudy.tjahjono@ukwms.ac.id>  
To: caroline cat <catcarol\_2000@yahoo.com>

Tue, May 21, 2019 at 2:12 PM

Sent from my iPhone

Begin forwarded message:

[Quoted text hidden]

---

**Revision requested for PRO\_2019\_9**

2 messages

**MICHAL SCHWARTZMAN (Prostaglandins and Other Lipid Mediators)**

&lt;EvisSupport@elsevier.com&gt;

Reply-To: polm@nymc.edu

To: yudy.tjahjono@ukwms.ac.id

Thu, May 16, 2019 at  
1:30 AM

Ref: PRO\_2019\_9

Title: Evaluation of Analgesic and Antiplatelet Activity of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid

Journal: Prostaglandins and Other Lipid Mediators

Dear Mr. tjahjono,

Thank you for submitting your manuscript to Prostaglandins and Other Lipid Mediators. I have completed the review of your manuscript and a summary is appended below. The reviewers recommend reconsideration of your paper following major revision. I invite you to resubmit your manuscript after addressing all reviewer comments.

When resubmitting your manuscript, please carefully consider all issues mentioned in the reviewers' comments, outline every change made point by point, and provide suitable rebuttals for any comments not addressed.

To submit your revised manuscript:

- Log into EVISE® at: [http://www.evise.com/evise/faces/pages/navigation/NavController.jsp?JRNL\\_ACR=PRO](http://www.evise.com/evise/faces/pages/navigation/NavController.jsp?JRNL_ACR=PRO)
- Locate your manuscript under the header 'My Submissions that need Revisions' on your 'My Author Tasks' view
- Click on 'Agree to Revise'
- Make the required edits
- Click on 'Complete Submission' to approve

**What happens next?**

After you approve your submission preview you will receive a notification that the submission is complete. To track the status of your paper throughout the editorial process, log in to Evise® at: [http://www.evise.com/evise/faces/pages/navigation/NavController.jsp?JRNL\\_ACR=PRO](http://www.evise.com/evise/faces/pages/navigation/NavController.jsp?JRNL_ACR=PRO).

**Enrich your article to present your research with maximum impact.** This journal supports the following [Content Innovations](#):

Data in Brief (optional)

We invite you to convert your supplementary data (or a part of it) into a Data in Brief article. Data in Brief articles are descriptions of the data and associated metadata which are normally buried in supplementary material. They are actively reviewed, curated, formatted, indexed, given a DOI and freely available to all upon publication. Data in Brief should be uploaded with your revised manuscript directly to Prostaglandins and Other Lipid Mediators. If your Prostaglandins and Other Lipid Mediators research article is accepted, your Data in Brief article will automatically be transferred over to our new, fully Open Access journal, Data in Brief, where it will be editorially reviewed and published as a separate data article upon acceptance. The Open Access fee for Data in Brief is \$500.

Please just fill in the template found here:

[http://www.elsevier.com/inca/publications/misc/dib\\_data%20article%20template\\_for%20other%20journals.docx](http://www.elsevier.com/inca/publications/misc/dib_data%20article%20template_for%20other%20journals.docx). Then, place all Data in Brief files (whichever supplementary files you would like to include as well as your completed Data in Brief template) into a .zip file and upload this as a Data in Brief item alongside your Prostaglandins and Other Lipid Mediators revised manuscript. Note that only this Data in Brief item will be transferred over to Data in Brief, so ensure all of your relevant Data in Brief documents are zipped into a single file. Also, make sure you change references to supplementary material in your Prostaglandins and Other Lipid Mediators manuscript to reference the Data in Brief article where appropriate.

Questions? Please send your inquiries to [dib@elsevier.com](mailto:dib@elsevier.com). Example Data in Brief can be found here: <http://www.sciencedirect.com/science/journal/23523409>

I look forward to receiving your revised manuscript as soon as possible.

Kind regards,

Dr SCHWARTZMAN  
Editor-in-Chief  
Prostaglandins and Other Lipid Mediators

**Comments from the editors and reviewers:**

**-Reviewer 1**

-

Kuncoro Foe and colleagues demonstrated that a new compound related to salicylic acid namely 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid had an excellent analgesic effect with no toxicity impact, better than acetylsalicylic acid. They synthesized this new compound which is a relatively simple and easy method. The experimental data convincing and the written results and methods are understandable. However, minor comment will be addressed before accepting the publication.

Description of the histological layers on the Fig.2 is essential to understand the orientation. The authors can keep the abbreviations on the figure and detailed microscopic layers in the figure legend. On Fig.2A, 400X can be removed and it does not say anything. Bars as mentioned in the figure legend has 200 but, on the figure, as 1 mm. Correct it. Authors are advised to keep the same magnification in all three pictures. Most importantly, the pictures are with low quality and blur. Better new pictures with focused plane improve the results.

**-Reviewer 2**

-

There significant novelty in this research paper, the authors develop new derivation drug form of aspirin for better platelet aggregation and lower oral toxicity than the conventional aspirin. The *in vivo* experiments were conducted with detail to provide concise description of synthesized drug. The paper can be accepted after following these revisions.

1. Section 2.2, 3.1, 4.1 should be changed into characterization.
2. There are two lines in Figure 3 and 4, please put legend to define each lines.
3. In section 4.1, the authors mention that they use pyridine as the catalyst. Based on scheme 1, pyridine is actually transformed into salt form. Normally, catalyst does not involve in a reaction since their purpose only lower the activation energy of the system. Please clarify the discussion in section 4.1.
4. The sentence "Pyridine could convert phenolic hydroxyl moieties into a good leaving group" is confusing. What does a good leaving group mean?
5. Please explain the reason of using acetone as the solvent. Is it possible to change it with other organic solvents to negotiate the danger of acetone toward the environment hazard?
6. In section 4.2, 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid has higher CLogP than acetylsalicylic acid, but both have same values of polarizability and CMR. Is it possible?
7. ASA has non selective inhibition toward COX-1 and COX-2, so it leads to the disruption of the integrity of healthy gastric mucosal layer. But 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid can maintain the integrity if gastric mucosal layer. Please explain it based on the concentration dependent experiment.
8. Please explain briefly the comparison of the synthesized drug and ASA for the inhibition of COX2 with regards of time dependent contact of mucosal layer.
9. There are some grammatical error in this manuscript, please check it thoroughly.

**MethodsX (optional)**

We invite you to submit a method article alongside your research article. This is an opportunity to get full credit for the time and money you have spent on developing research methods, and to increase the visibility and impact of your work.

If your research article is accepted, your method article will be automatically transferred over to the open access journal, MethodsX, where it will be editorially reviewed and published as a separate method article upon acceptance. Both articles will be linked on ScienceDirect.

Please use the MethodsX template available here when preparing your article: <https://www.elsevier.com/MethodsX-template>. Open access fees apply.

**Have questions or need assistance?**

For further assistance, please visit our [Customer Support](#) site. Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about EVISE® via interactive tutorials. You can also talk 24/5 to our customer support team by phone and 24/7 by live chat and email.

-----  
Copyright © 2018 Elsevier B.V. | [Privacy Policy](#)

Elsevier [B.V.](#), [Radarweg 29](#), [1043 NX Amsterdam](#), [The Netherlands](#), Reg. No. 33156677.

---

**Yudy Tjahjono, B.Sc., M.Sc.Biol.** <yudy.tjahjono@ukwms.ac.id>  
To: caroline cat <catcarol\_2000@yahoo.com>

Tue, May 21, 2019 at 2:12 PM

Sent from my iPhone

Begin forwarded message:

[Quoted text hidden]

---

**Received revision PRO\_2019\_9\_R1**

1 message

**Prostaglandins and Other Lipid Mediators** <EvisSupport@elsevier.com>

Fri, Jul 5, 2019 at 2:28 PM

Reply-To: pro@elsevier.com

To: yudy.tjahjono@ukwms.ac.id

*This message was sent automatically.*

Ref: PRO\_2019\_9\_R1

Title: Evaluation of Analgesic and Antiplatelet Activity of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid

Journal: Prostaglandins and Other Lipid Mediators

Dear Mr. tjahjono,

Thank you for submitting your revised manuscript for consideration for publication in Prostaglandins and Other Lipid Mediators. Your revision was received in good order.

To track the status of your manuscript, please log into EVISE® [http://www.evise.com/evise/faces/pages/navigation/NavController.jsp?JRNL\\_ACR=PRO](http://www.evise.com/evise/faces/pages/navigation/NavController.jsp?JRNL_ACR=PRO) and locate the submission under the header 'My Submissions with Journal' on your 'My Author Tasks' view.

We appreciate your submitting your revision to this journal.

Kind regards,

Prostaglandins and Other Lipid Mediators

**Have questions or need assistance?**

For further assistance, please visit our [Customer Support](#) site. Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about EVISE® via interactive tutorials. You can also talk 24/5 to our customer support team by phone and 24/7 by live chat and email.

-----  
Copyright © 2018 Elsevier B.V. | [Privacy Policy](#)

Elsevier [B.V.](#), [Radarweg 29](#), [1043 NX Amsterdam](#), [The Netherlands](#), Reg. No. 33156677.



Yudy Tjahjono <yudy.tjahjono@ukwms.ac.id>

---

## Reviews complete and decision pending for your manuscript PRO\_2019\_9\_R1

1 message

---

**Prostaglandins and Other Lipid Mediators** <EvisSupport@elsevier.com>

Wed, Jul 10, 2019 at 3:26 PM

Reply-To: pro@elsevier.com

To: yudy.tjahjono@ukwms.ac.id

Reference: PRO\_2019\_9\_R1

Title: Evaluation of Analgesic and Antiplatelet Activity of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid

Journal: Prostaglandins and Other Lipid Mediators

Dear Mr. tjahjono,

I am pleased to inform you that I have received all the required reviews, which I will now evaluate before making a decision on your manuscript referenced above.

In the event that I need to seek the opinion of an additional reviewer, you may see the status of your manuscript revert briefly from 'Ready for Decision' to 'Under Review'.

To track the status of your manuscript, please log into EVISE® [http://www.evise.com/evise/faces/pages/navigation/NavController.jsp?JRNL\\_ACR=PRO](http://www.evise.com/evise/faces/pages/navigation/NavController.jsp?JRNL_ACR=PRO) and go to 'My Submissions'.

I will inform you once I have made a decision.

Thank you again for submitting your manuscript to Prostaglandins and Other Lipid Mediators and for giving me the opportunity to consider your work.

Kind regards,

Prostaglandins and Other Lipid Mediators

### Have questions or need assistance?

For further assistance, please visit our [Customer Support](#) site. Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about EVISE® via interactive tutorials. You can also talk 24/5 to our customer support team by phone and 24/7 by live chat and email.

-----  
Copyright © 2018 Elsevier B.V. | [Privacy Policy](#)

Elsevier [B.V.](#), Radarweg 29, 1043 NX Amsterdam, The Netherlands, Reg. No. 33156677.



---

**Your manuscript PRO\_2019\_9\_R2 has been accepted**

2 messages

**MICHAL SCHWARTZMAN (Prostaglandins and Other Lipid Mediators)**

Sat, Jul 13, 2019 at 1:26

&lt;EvisSupport@elsevier.com&gt;

AM

Reply-To: polm@nymc.edu

To: yudy.tjahjono@ukwms.ac.id

Ref: PRO\_2019\_9\_R2

Title: Evaluation of Analgesic and Antiplatelet Activity of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid

Journal: Prostaglandins and Other Lipid Mediators

Dear Dr. Tjahjono,

I am pleased to inform you that your paper has been accepted for publication. My own comments as well as any reviewer comments are appended to the end of this letter.

Your accepted manuscript will now be transferred to our production department. We will create a proof which you will be asked to check. You can read more about this [here](#). Meanwhile, you will be asked to complete a number of online forms required for publication. If we need additional information from you during the production process, we will contact.

Thank you for submitting your work to Prostaglandins and Other Lipid Mediators. We hope you consider us again for future submissions.

Kind regards,

MICHAL SCHWARTZMAN, PhD  
Editor-in-Chief  
Prostaglandins and Other Lipid Mediators

**Comments from the editors and reviewers:****- Reviewer 2**

- The paper is ready to be published in this journal.

**Have questions or need assistance?**

For further assistance, please visit our [Customer Support](#) site. Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about EVISE® via interactive tutorials. You can also talk 24/5 to our customer support team by phone and 24/7 by live chat and email.

---

Copyright © 2018 Elsevier B.V. | [Privacy Policy](#)

Elsevier [B.V.](#), [Radarweg 29, 1043 NX Amsterdam, The Netherlands](#), Reg. No. 33156677.

---

**Yudy Tjahjono, B.Sc., M.Sc.Biol.** <yudy.tjahjono@ukwms.ac.id>

Sat, Jul 13, 2019 at 8:01 AM

To: polm@nymc.edu

Dear Professor Schwartzman,

Thank you very much for the opportunity given to participate as an Author in Prostaglandin and Lipid Mediators. It is our greatest Honor. Sure i will prioritize this journal for my future pharmacology-based article. Looking forward for your direction.

Best Regards,

Yudy Tjahjono,

Dept. Head of research and development department.  
Drug development and Pharmacology research group.  
Widya Mandala Catholic University  
Surabaya-Indonesia  
[yudy.tjahjono@ukwms.ac.id](mailto:yudy.tjahjono@ukwms.ac.id)

[Quoted text hidden]

---

**Your manuscript PRO\_2019\_9\_R2 has been accepted**

2 messages

**MICHAL SCHWARTZMAN (Prostaglandins and Other Lipid Mediators)**

Sat, Jul 13, 2019 at 1:26 AM

&lt;EvisSupport@elsevier.com&gt;

Reply-To: polm@nymc.edu

To: yudy.tjahjono@ukwms.ac.id

Ref: PRO\_2019\_9\_R2

Title: Evaluation of Analgesic and Antiplatelet Activity of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid

Journal: Prostaglandins and Other Lipid Mediators

Dear Dr. Tjahjono,

I am pleased to inform you that your paper has been accepted for publication. My own comments as well as any reviewer comments are appended to the end of this letter.

Your accepted manuscript will now be transferred to our production department. We will create a proof which you will be asked to check. You can read more about this [here](#). Meanwhile, you will be asked to complete a number of online forms required for publication. If we need additional information from you during the production process, we will contact.

Thank you for submitting your work to Prostaglandins and Other Lipid Mediators. We hope you consider us again for future submissions.

Kind regards,

MICHAL SCHWARTZMAN, PhD  
Editor-in-Chief  
Prostaglandins and Other Lipid Mediators

**Comments from the editors and reviewers:****- Reviewer 2**

- The paper is ready to be published in this journal.

**Have questions or need assistance?**

For further assistance, please visit our [Customer Support](#) site. Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about EVISE® via interactive tutorials. You can also talk 24/5 to our customer support team by phone and 24/7 by live chat and email.

---

Copyright © 2018 Elsevier B.V. | [Privacy Policy](#)

Elsevier [B.V.](#), [Radarweg 29, 1043 NX Amsterdam, The Netherlands](#), Reg. No. 33156677.

---

**Yudy Tjahjono, B.Sc., M.Sc.Biol.** <yudy.tjahjono@ukwms.ac.id>

Sat, Jul 13, 2019 at 8:01 AM

To: polm@nymc.edu

Dear Professor Schwartzman,

Thank you very much for the opportunity given to participate as an Author in Prostaglandin and Lipid Mediators. It is our greatest Honor. Sure i will prioritize this journal for my future pharmacology-based article. Looking forward for your direction.

Best Regards,

Yudy Tjahjono,

Dept. Head of research and development department.  
Drug development and Pharmacology research group.  
Widya Mandala Catholic University  
Surabaya-Indonesia  
[yudy.tjahjono@ukwms.ac.id](mailto:yudy.tjahjono@ukwms.ac.id)

[Quoted text hidden]